Vistagen Therapeutics Stock Price on October 22, 2024
| VTGN Stock | USD 2.48 0.03 1.20% |
Below is the normalized historical share price chart for VistaGen Therapeutics extending back to June 21, 2011. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of VistaGen Therapeutics stands at 2.48, as last reported on the 12th of December 2024, with the highest price reaching 2.48 and the lowest price hitting 2.48 during the day.
If you're considering investing in VistaGen Stock, it is important to understand the factors that can impact its price. VistaGen Therapeutics owns Efficiency Ratio (i.e., Sharpe Ratio) of -0.15, which indicates the firm had a -0.15% return per unit of risk over the last 3 months. VistaGen Therapeutics exposes twenty-one different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate VistaGen Therapeutics' Risk Adjusted Performance of (0.09), coefficient of variation of (776.84), and Variance of 6.74 to confirm the risk estimate we provide.
At this time, VistaGen Therapeutics' Issuance Of Capital Stock is very stable compared to the past year. As of the 12th of December 2024, Stock Based Compensation To Revenue is likely to grow to 2.15, while Common Stock Shares Outstanding is likely to drop about 11.6 M. . As of the 12th of December 2024, Price Earnings To Growth Ratio is likely to grow to 53.85, while Price To Sales Ratio is likely to drop 56.54. VistaGen Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 6th of May 2016 | 200 Day MA 3.7048 | 50 Day MA 2.9026 | Beta 0.778 |
VistaGen |
Sharpe Ratio = -0.1515
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | VTGN |
Estimated Market Risk
| 2.61 actual daily | 23 77% of assets are more volatile |
Expected Return
| -0.4 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.15 actual daily | 0 Most of other assets perform better |
Based on monthly moving average VistaGen Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of VistaGen Therapeutics by adding VistaGen Therapeutics to a well-diversified portfolio.
Price Book 0.7517 | Enterprise Value Ebitda (0.19) | Price Sales 82.2944 | Shares Float 16.3 M | Wall Street Target Price 13 |
Related Headline
Zentalis Pharmaceuticals Headline on 22nd of October 2024
Undervalued Opportunities US Penny Stocks To Watch In Octobe... by simplywall.st
The U.S. stock market has recently shown mixed performance, with the Nasdaq rising due to gains in technology stocks like Nvidia, while the Dow Jones and SP 500 have pulled back from record highs. Amid these fluctuations, investors are exploring various opportunities across different market segments. Penny stocks, often associated with smaller or emerging companies, continue to attract attention for their potential value and growth prospects despite their somewhat outdated label. In this...
VistaGen Therapeutics Valuation on October 22, 2024
It is possible to determine the worth of VistaGen Therapeutics on a given historical date. On October 22, 2024 VistaGen was worth 3.02 at the beginning of the trading date compared to the closed value of 3.1. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of VistaGen Therapeutics stock. Still, in general, we apply an absolute valuation method to find VistaGen Therapeutics' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of VistaGen Therapeutics where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against VistaGen Therapeutics' related companies.
| Open | High | Low | Close | Volume | |
| 3.10 | 3.16 | 3.00 | 3.00 | 142,799 | |
10/22/2024 | 3.02 | 3.15 | 3.02 | 3.10 | 191,613 |
| 3.13 | 3.17 | 3.02 | 3.03 | 104,500 |
| Backtest VistaGen Therapeutics | | | VistaGen Therapeutics History | | | VistaGen Therapeutics Valuation | Previous | Next |
VistaGen Therapeutics Trading Date Momentum on October 22, 2024
| On October 23 2024 VistaGen Therapeutics was traded for 3.03 at the closing time. The top price for the day was 3.17 and the lowest listed price was 3.02 . The trading volume for the day was 104.5 K. The trading history from October 23, 2024 was a factor to the next trading day price decrease. The trading price change against the next closing price was 2.26% . The trading price change against the current closing price is 0.00% . |
VistaGen Therapeutics Fundamentals Correlations and Trends
By evaluating VistaGen Therapeutics' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among VistaGen Therapeutics' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. VistaGen financial account trend analysis is a perfect complement when working with valuation or volatility modules.About VistaGen Therapeutics Stock history
VistaGen Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for VistaGen is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in VistaGen Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing VistaGen Therapeutics stock prices may prove useful in developing a viable investing in VistaGen Therapeutics
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 19.4 M | 11.6 M | |
| Net Loss | -53.3 M | -50.7 M |
VistaGen Therapeutics Stock Technical Analysis
VistaGen Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
VistaGen Therapeutics Period Price Range
Low | December 12, 2024
| High |
0.00 | 0.00 |
VistaGen Therapeutics cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
VistaGen Therapeutics December 12, 2024 Market Strength
Market strength indicators help investors to evaluate how VistaGen Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading VistaGen Therapeutics shares will generate the highest return on investment. By undertsting and applying VistaGen Therapeutics stock market strength indicators, traders can identify VistaGen Therapeutics entry and exit signals to maximize returns
VistaGen Therapeutics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for VistaGen Therapeutics' price direction in advance. Along with the technical and fundamental analysis of VistaGen Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of VistaGen to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | (0.09) | |||
| Jensen Alpha | (0.40) | |||
| Total Risk Alpha | (0.76) | |||
| Treynor Ratio | (0.72) |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in VistaGen Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in VistaGen Stock, please use our How to Invest in VistaGen Therapeutics guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of VistaGen Therapeutics. If investors know VistaGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about VistaGen Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.74) | Revenue Per Share 0.029 | Quarterly Revenue Growth (0.34) | Return On Assets (0.39) | Return On Equity (0.62) |
The market value of VistaGen Therapeutics is measured differently than its book value, which is the value of VistaGen that is recorded on the company's balance sheet. Investors also form their own opinion of VistaGen Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is VistaGen Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because VistaGen Therapeutics' market value can be influenced by many factors that don't directly affect VistaGen Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between VistaGen Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if VistaGen Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, VistaGen Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.